France
· Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 137.71 million. The enterprise value is 138.88 million.
| Market Cap | 137.71M |
| Enterprise Value | 138.88M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 27.99% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 47.40M |
| Shares Change (YoY) | +27.99% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 3.36% |
| Owned by Institutions (%) | 18.71% |
| Float | 26.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -19.15 |
| PB Ratio | -2.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.81 |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 0.98 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.50 |
| Interest Coverage | -8.44 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -52.89% |
| Return on Invested Capital (ROIC) | -251.54% |
| Return on Capital Employed (ROCE) | -804.64% |
| Revenue Per Employee | -66,574 |
| Profits Per Employee | -630,852 |
| Employee Count | 108 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.48% in the last 52 weeks. The beta is 1.55, so Nanobiotix's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -49.48% |
| 50-Day Moving Average | 3.27 |
| 200-Day Moving Average | 3.80 |
| Relative Strength Index (RSI) | 37.98 |
| Average Volume (20 Days) | 117,929 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR -7.19 million and -68.13 million in losses. Loss per share was -1.44.
| Revenue | -7.19M |
| Gross Profit | -7.19M |
| Operating Income | -68.26M |
| Pretax Income | -68.03M |
| Net Income | -68.13M |
| EBITDA | -67.67M |
| EBIT | -68.26M |
| Loss Per Share | -1.44 |
Balance Sheet
The company has 49.74 million in cash and 50.90 million in debt, giving a net cash position of -1.17 million or -0.02 per share.
| Cash & Cash Equivalents | 49.74M |
| Total Debt | 50.90M |
| Net Cash | -1.17M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -65.70M |
| Book Value Per Share | -1.39 |
| Working Capital | 2.53M |
Cash Flow
In the last 12 months, operating cash flow was -19.55 million and capital expenditures -846,000, giving a free cash flow of -20.40 million.
| Operating Cash Flow | -19.55M |
| Capital Expenditures | -846,000 |
| Free Cash Flow | -20.40M |
| FCF Per Share | -0.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | 949.35% |
| Pretax Margin | 946.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.99% |
| Shareholder Yield | -27.99% |
| Earnings Yield | -49.47% |
| FCF Yield | -14.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.73. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.73 |
| Piotroski F-Score | n/a |